Analysts Offer Predictions for Minerva Neurosciences Inc’s FY2018 Earnings (NERV)

Minerva Neurosciences Inc (NASDAQ:NERV) – Equities researchers at Jefferies Financial Group increased their FY2018 earnings per share (EPS) estimates for shares of Minerva Neurosciences in a research note issued to investors on Monday, November 5th. Jefferies Financial Group analyst B. Amin now anticipates that the biopharmaceutical company will earn ($1.28) per share for the year, up from their prior forecast of ($1.39). Jefferies Financial Group also issued estimates for Minerva Neurosciences’ Q4 2018 earnings at ($0.33) EPS, FY2019 earnings at ($1.48) EPS, FY2020 earnings at ($1.86) EPS, FY2021 earnings at ($1.53) EPS and FY2022 earnings at ($0.30) EPS.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.07.

A number of other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 9th. ValuEngine raised shares of Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 23rd. Citigroup raised their target price on shares of Minerva Neurosciences to $19.00 in a research report on Friday, August 3rd. Finally, Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Friday.

Shares of Minerva Neurosciences stock opened at $9.55 on Thursday. The firm has a market capitalization of $377.83 million, a price-to-earnings ratio of -8.84 and a beta of 1.66. Minerva Neurosciences has a 12-month low of $4.80 and a 12-month high of $12.95.

Several large investors have recently bought and sold shares of NERV. Dimensional Fund Advisors LP lifted its position in shares of Minerva Neurosciences by 328.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 278,580 shares of the biopharmaceutical company’s stock worth $1,741,000 after purchasing an additional 213,583 shares during the period. Millennium Management LLC lifted its position in shares of Minerva Neurosciences by 353.6% in the 1st quarter. Millennium Management LLC now owns 894,379 shares of the biopharmaceutical company’s stock worth $5,590,000 after purchasing an additional 697,219 shares during the period. Handelsbanken Fonder AB lifted its position in shares of Minerva Neurosciences by 31.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 125,000 shares of the biopharmaceutical company’s stock worth $1,031,000 after purchasing an additional 30,000 shares during the period. Acadian Asset Management LLC lifted its position in shares of Minerva Neurosciences by 329.4% in the 2nd quarter. Acadian Asset Management LLC now owns 32,060 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 24,594 shares during the period. Finally, Northpointe Capital LLC purchased a new stake in shares of Minerva Neurosciences in the 2nd quarter worth about $2,110,000. 72.38% of the stock is owned by hedge funds and other institutional investors.

In other news, COO Joseph H. Reilly sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $12.06, for a total value of $301,500.00. Following the completion of the sale, the chief operating officer now directly owns 29,177 shares of the company’s stock, valued at approximately $351,874.62. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William F. Doyle bought 4,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was bought at an average cost of $9.88 per share, with a total value of $39,520.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at approximately $39,520. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 8,600 shares of company stock valued at $87,520 and sold 131,717 shares valued at $1,576,610. Company insiders own 9.60% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Read More: Short Selling Stocks and Day Traders

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply